Home  »  Ipo Review  »  Glenmark Life Sciences Ipo

Let’s have a detailed review of the company and analytics of the Glenmark Life Sciences IPO release date, IPO offer price, subscription, Glenmark Life Sciences Limited IPO allotment, grey market price, and other details like the company’s background, its financial positions, its promoters, and other related things.

Face ValueRs 2
 Price BandRs 695 to Rs 720
Listing AtBSE, NSE
Min. Order Quantity20 Shares
Listing DateAug 6, 2021
Offer for SaleRs 4536 Million
Fresh IssueRs 10,600 Million
IPO SizeRs 15,136 Million
Tick Size1

Glenmark Life Sciences IPO is listed at a [●] premium. Check out the live share price by clicking on the below link.

Glenmark Life Sciences IPO – Summary

Glenmark Life Sciences IPOThey are a leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients (“APIs”) in chronic therapeutic areas, including cardiovascular disease (“CVS”), central nervous system disease (“CNS”), pain management, and diabetes. They also manufacture and sell APIs for gastro-intestinal disorders, anti-infectives, and other therapeutic areas.

their API portfolio comprises specialized and profitable products, including niche and technically complex molecules, which they believe reflects their capability to branch into other high-value products. They have a strong market share in select specialized APIs

The Promoter of this company is Mr. GLENMARK PHARMACEUTICALS LIMITED. The lead manager to the issue is Kotak Mahindra Capital Company Limited, BofA Securities India Limited, Goldman Sachs (India) Securities Private Limited, Goldman Sachs (India) Securities Private Limited, BOB Capital Markets Limited, SBI Capital Markets Limited and the Registrar to this issue is KFin Technologies Private Limited.

Glenmark Life Sciences IPO Date

The opening and the closing date of the IPO of Glenmark Life Sciences Limited are Jul 27, 2021, and Jul 29, 2021, respectively.

Check out Related IPO Links:

Glenmark Life Science GMP
Allotment – Glenmark Life Science IPO 

Glenmark Life Sciences IPO Subscription

Day / DateQIBNIIRIITotal Subscription
1st Day – 27 July0.00x0.86x5.17x2.78x
2nd Day – 28 July1.38x3.39x9.28x5.78x
5th Day – 29 July36.97x122.54x14.63x44.17x
Shares Offered or Net Issue4,242,3793,232,7707,543,13015,018,279

The shares subscribed by the public will be updated here.

Check Glenmark Life Sciences IPO LIVE Subscription

  • Glenmark Life Sciences IPO LIVE Bid details on BSE
  • Glenmark Life Sciences IPO LIVE Bid details on NSE

For the Latest Bid details click on the above links.

Glenmark Life Sciences IPO Allotment Status

Here, you can find the Allotment Status of this IPO.

Allotment of Equity Shares under the Fresh Issue and transfer of the Offered Shares of the Promoter Selling Shareholders according to the Offer for Sale to the successful Bidders. However, the Allotment Status is not yet disclosed.

Glenmark Life Sciences Limited IPO Listing Date

Find the dates below on basis of allotment, refund, listing, and more:

Basis of Allotment FinalizationAug 3, 2021
Refunds InitiationAug 4, 2021
Credit of Shares to Demat AccountAug 5, 2021
Share Listing DateAug 6, 2021

Glenmark Life Sciences IPO Price Band

The face value of each share is Rs.2, but the price band of the IPO is Rs 695 to Rs 720 

Glenmark Life Sciences IPO Equity Size

This Initial Public Issue of X Equity Shares of Rs.2 each for cash at Rs 695 to Rs 720 per equity share aggregating to Rs.15,136 Million.

Glenmark Life Sciences IPO Share Offering

Fresh Issue: The Issue (excluding the Market Maker Reservation Portion) of [●] Equity Shares of Rs.2/ each.

Issue Size: X Equity Shares of Rs.2 each, aggregating to Rs.15,136 Million

Open Free Demat Account Now!

    Fill Your Details Here

    Glenmark Life Sciences IPO – Live Performance

    The listing date of this IPO is [●]. You can check the live performance of the IPO here, only after it is listed on exchanges.

    Live IPO Performance – Glenmark Life Sciences Share Price

    Glenmark Life Sciences IPO Grey Market Premium

    The Glenmark Life Sciences Limited IPO Grey Market Premium price is Rs 90, the Kostak rate is Rs 0 and the Subject to Sauda is 0. 

    Glenmark Life Sciences IPO – Company Overview

    They are a wholly-owned subsidiary of their Promoter, Glenmark Pharmaceuticals Limited (“Glenmark”), a research-oriented, innovation-led, global pharmaceutical company, which was established in 1977 and is listed on the BSE and NSE.

    In 2001-2002, Glenmark launched the API manufacturing business by setting up a manufacturing facility in Kurkumbh in the state of Maharashtra, India, and focused on growing this business over the next 18 years.

    In 2019, the API manufacturing business of Glenmark was sold and spun off into their Company as part of a broader reorganization designed to place Glenmark on an accelerated trajectory to attain its objectives in three different verticals, with their Company focusing on the API business. Following the Spin-off, they operate as an independent, professionally managed global API business.

    They believe that maintaining high standards of process innovation and quality in their R&D and manufacturing operations is critical to their brand and maintenance of long-term relationships with their customers.

    Glenmark Life Sciences IPO – Financial Statements

    A quick look into the past financial performance of the company to understand its performance of the business and evaluate the growth prospectus:

    Financial Summary:

    Amount (in INR & Million)
    Total Assets19,970.7517,256.0414,753.95
    *Total Revenue18,859.7615,493.038,868.65
    Total Expense14,150.3211,282.366,585.68
    Profit After Tax3,515.813,130.981,955.92

    Earnings per Equity Share (in Million)

    Basic & Diluted32.6129.0424.64


    Glenmark Life Sciences IPO – Promoters

    The Promoter of this company is:


    List of Related Parties (Key Managerial Personnel)

    • Glenn Saldanha, Chairman, and Non-Executive Director
    • V.S Mani, Non-Executive Director
    • Yasir Rawjee, Managing Director and Chief Executive Officer
    • Sumantra Mitra, Executive Director
    • Sridhar Gorthi, Independent Director

    Glenmark Life Sciences IPO – Promoters Holding

    • Pre Issue Share Holding – NA %
    • Pos Issue Share Holding – NA %

    Glenmark Life Sciences IPO Offer Details or Issue Details

     Particulars No. Of Equity Shares
     Equity Shares Offered Up to X Equity Shares aggregating up to Rs.15,136 Million
    of which:
    Issue Reserved for the Market MakersUp to [●] Equity Shares aggregating up to Rs.[●]
    Net Issue to the PublicUp to [●] Equity Shares aggregating up to Rs.[●]
    Of which:
    Retail Investors Portion Not less than [●] Equity Shares
    Other than Retail Individual InvestorsNot more than [●] Equity Shares
     Equity Shares outstanding before the Issue10,78,04,950 Equity Shares
     Equity Shares outstanding after the IssueX Equity Shares

    Glenmark Life Sciences IPO Issue Object

    Their Company proposes to utilize the Net Proceeds towards funding the following objects:

    1. Payment of outstanding purchase consideration to the Promoter for the spin-off of the API business from the Promoter into their Company according to the Business Purchase Agreement
    2. Funding capital expenditure requirements
    3. General corporate purposes

    Glenmark Life Sciences IPO – Business Strategy

    • Any manufacturing or quality control problems may subject them to regulatory action, damage their reputation, and have an adverse effect on their business, results of operations, financial condition, and cash flow
    • The loss of one or more of their key customers, the deterioration of their financial condition or prospects, or a reduction in their demand for their products.
    • In the event, their API business or products in specific therapeutic categories or their products do not perform as well as expected or if substitute products become available or gain wider market acceptance.
    • Slowdown or shutdown in their manufacturing operations.
    • Delay, interruption, or reduction in the supply of raw materials to manufacture their products.
    • Pricing pressure from customers may affect their gross margin, profitability, and ability to increase their prices.
    • Counterparty credit risk and any delay in receiving payments or non-receipt of payments.
    • Failure to obtain, maintain or renew their statutory and regulatory licenses, permits, and approvals required to operate their business.
    • Inability to accurately forecast demand for their products and manage their inventory

    Glenmark Life Sciences IPO – Basis of Offer Price

    The issue price is determined by the company in consultation with the Lead manager based on the following qualitative and quantitative factors.

    Qualitative factors are:

    • Leadership in select high value, non-commoditized APIs in chronic therapeutic areas
    • Strong relationships with leading global generic companies
    • Quality-focused compliant manufacturing and R&D infrastructure
    • Strong focus on sustainability in operations
    • Cost leadership across products through careful monitoring and continuous effort
    • Experienced management team with a proven track record

    The relevant quantitative factors are:

    Basic & Diluted EPSRONW (%)NAV (Rs.)

    Glenmark IPO: Competitive Peers

    Face Value (Rs.)P/EEPS  Basic (Rs.)EPS  Diluted (Rs.)
    Return on Net Worth (%)Total Income (Rs. in Million)
    Glenmark Life Sciences Limited2[●]32.6132.6146.7118,859.76
    Listed Peers
    Divis Laboratories Limited263.6574.7574.7521.3570,319.60
    Laurus Labs Limited236.5918.3618.2837.8748,358.60
    Shilpa Medicare Limited133.3718.1318.139.999,312.72
    Aarti Drugs Limited1024.2830.0930.0930.7021,593.10
    Solara Active Pharma
    Sciences Limited

    Glenmark Life Sciences IPO Lead Managers

    Lead Managers

    Kotak Mahindra Capital Company Limited

    BofA Securities India Limited

    Goldman Sachs (India) Securities Private Limited

    DAM Capital Advisors Limited

    BOB Capital Markets Limited

    SBI Capital Markets Limited

    Glenmark Life Sciences IPO Registrar to offer

    Registrar to the Offer
    KFin Technologies Private Limited (Formerly known as
    Karvy Fintech Private Limited)
    Selenium Tower-B
    Plot No-31 and 32, Financial District
    Nanakramguda, Serilingampally
    Hyderabad, Rangareddi 500032
    Telangana, India
    Tel: +91 40 6716 2222
    E-mail: glenmark.ipo@kfintech.com
    Investor Grievance E-mail: einward.ris@kfintech.com
    Website: www.kfintech.com
    Contact Person: M Murali Krishna
    SEBI Registration No.: INR000000221

    Glenmark IPO – Other Details

    • Statutory Auditor – Walker Chandiok & Co LLP
    • Legal Counsel to the Company – Trilegal
    • Bankers to the Company –  Bank of Baroda, and State Bank of India

    Glenmark IPO Review by Stock Brokers

    Top Stock Brokers ReviewCompany ReputationCompetitive EdgeFinancial StatementPopularity IndexPromoters Reputation
    Angel Broking7.5/107.4/108.5/108.1/107.1/10
    Kotak Securities7.3/107.5/108.4/108.1/107.3/10
    ICICI Direct7.3/107.3/108.7/108.1/107.1/10
    Motilal Oswal7.1/107.1/108.6/108.3/107.2/10


    Subscribe to Glenmark Life Sciences IPO

      Fill Your Details Here

      Glenmark Life Sciences Limited IPO News

      News 1 – Glenmark Life Sciences Limited IPO DRHP Download

      News 2 – Glenmark IPO RHP Download

      Glenmark Life Sciences IPO Review FAQs

      What is the Issue Size of Glenmark Life Sciences IPO?

      The Company is making an initial public offer of NA equity shares. They vividly portray the aspects of the issue in this article. You can check the stats on the fresh issue, Offer for sale, and net issue.

      What is the Price band of Glenmark Life Sciences IPO?

      The price band for this particular IPO, i.e. Glenmark Life Sciences IPO ranges between Rs 695 to Rs 720. As far as the face value of the share is of concern, it is Rs.2 per share.

      What is the Glenmark Life Sciences IPO Open Date?

      The opening and closing dates for Glenmark Life Sciences IPO have been updated. The IPO is set to open on Jul 27, 2021, while the closing date is set at Jul 29, 2021.

      What is the Glenmark IPO Allotment Date?

      They also have the news regarding the respective allotment dates of the Glenmark Life Sciences IPO. Basis of Allotment finalization is on Aug 3, 2021, refund initiation is on Aug 4, 2021, credit of shares is on Aug 5, 2021, and share listing date is on Aug 6, 2021.

      What is the Glenmark IPO Listing Date?

      Shares of Glenmark Life Sciences shall be listed in the exchanges on Aug 6, 2021. The date, when the listing would be done, is stagnant on Aug 6, 2021.

      Who is the Registrar of Glenmark IPO?

      One of the reputed registrars is managing the issue of Glenmark Life Sciences IPO, i.e. KFin Technologies Private Limited. their website will help you regarding the further information you are on the lookout for.

      Who is the Promoter of Glenmark IPO?

      Here are the promoters of Glenmark Life Sciences – GLENMARK PHARMACEUTICALS LIMITED. You can refer to the RHP for further information on the promoter. You will find the link to RHP in the article.

      What is the GMP of Glenmark Life Sciences IPO?

      They have obtained the GMP of Glenmark Life Sciences IPO and it is Rs 90. Further insights of Kostak rate and subject to sauda or SS are as well included in this report.

      Is Glenmark IPO good for Investment?

      They have further provided the financial status of the company in this article, from the past few years. You can refer to the same, and also check the line of operations they are into and then decide to invest in the IPO.

      What is the PAT of Glenmark Life Sciences?

      They have the information of company financials, and according to that, they have the figures from the last few years to provide. PAT for the financial year 2021 in Million is 3,515.81, 2020 is 3,130.98, 2019 is 1,955.92.

      Calculate your return on investment!

      Asset ClassROI (Rs.)Profit (Rs.)Profit (%)
      Real Estate
      Fixed Deposit
      Mutual Fund

      Market Guide

      Featured Topics


      Leave a Reply

      Your email address will not be published. Required fields are marked *

      24 + 9 =

      Get 100% IPO Allotment Guarantee! Subscribe to IPO